

Instructions for Authors

Scope

Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans. The following topics are of special interest: descriptive, analytical, biochemical and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention.

Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and physical carcinogens, environmental contaminants, dietary components and behavioral factors such as tobacco use and sun exposure.

Besides welcoming manuscripts that address individual subjects in any of the three disciplines, the Editors encourage the submission of manuscripts with an interdisciplinary approach.

Contents

- Original research articles
- Invited editorials
- Selected review articles
- Short communications
- Letters to the editor
- Meeting reports
- AACR and ASPO news

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the American Medical Association, 535 North Dearborn Street, Chicago, IL 60610.

Journal policy requires that authors, reviewers, and Associate Editors reveal to the Editor-in-Chief any relationships that they believe could be construed as causing a conflict of interest with regard to the manuscript submitted for review.

Manuscript Submission

Mail manuscripts directly to Dr. Pelayo Correa, Editor-in-Chief. Submit four original sets (not photocopies) of illustrations along with four copies of the manuscript. Illustrations will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. FAX transmission and overnight delivery service will be used to expedite review and publication.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 × 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors, and affiliations;
2. A running title of fewer than 50 characters;
3. Text, arranged in this order: Abstract (not more than 250 words), Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References;
4. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
5. Tables, on pages separate from the text, with descriptive titles and/or legends;
6. Figure legends, on pages separate from the text. Define all symbols and include staining for halftones, where applicable.

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

Sample references:

1. Fontham, E. T. H., Correa, P., Wu-Williams, A., Reynolds, P., Greenberg, R. S., Buffler, P. A., Chen, V. W., Boyd, P., Alterman, T., Austin, D. F., Liff, J., and Greenberg, S. D. Lung cancer in nonsmoking women: A multicenter case-control study. *Cancer Epidemiol., Biomarkers & Prev.*, 1: 35-43, 1991.
2. Reznikoff, C. A., Swaminathan, S., and Verma, A. K. Cultured normal human uroepithelial cells: a new system for *in vitro* carcinogenesis studies. In: M. Webber and L. Sikeley (eds.), *In Vitro Models for Cancer Research*, pp. 63-101. Boca Raton, FL: CRC Press, 1986.

Illustrations

Provide four original sets of illustrations (whether line-cut drawings or halftones). Label each figure in pencil on the reverse side with the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on illustrations should not be larger than 12-point type. All illustrations will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with the greatest fidelity.

The complete expense of reproducing color photographs will be charged to the author. Submit color illustrations on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. **Proofs not received by the deadline will be published without the authors' corrections.** Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Authors will be charged for all changes in proof not due to printer's errors. Each author's alteration in any line of text costs approximately \$6.10. Lengthy insertions of entire sentences or paragraphs are billed at different rates depending upon the complexity of the alterations.

Typesetting Manuscripts from Computer Disks

Cancer Epidemiology, Biomarkers & Prevention welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission and a form which must be completed and returned with your disk to the AACR Publications Department within 48 hours of notification of acceptance. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For More Information, Contact:

Dr. Pelayo Correa, Editor-in-Chief, CEBP, Department of Pathology, Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393. Telephones: (504)529-2848; (504)568-6035; FAX: (504)529-2849.

Or:

Publications Department, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215)440-9300; FAX: (215)440-9355.

AACR SPECIAL CONFERENCE IN CANCER RESEARCH



Cancer Susceptibility Genes and Molecular Carcinogenesis

February 19-25, 1996
The Keystone Resort, Keystone, Colorado

CONFERENCE CHAIRPERSONS

Allan Balmain / Glasgow, Scotland
Curtis C. Harris / Bethesda, MD
Kenneth Olden / Research Triangle Park, NC

SCIENTIFIC PROGRAM

Keynote Address

Harold Varmus / Bethesda, MD

Genetic Susceptibility of Animal Models - Inbred Strains

Norman R. Drinkwater / Madison, WI
Cheryl Lyn Walker / Smithville, TX
Peter Demant / Amsterdam, The Netherlands

Genetic Susceptibility of Animal Models - Transgenic and Knockout

Douglas Hanahan / San Francisco, CA
Tyler E. Jacks / Cambridge, MA
Michael P. Rosenberg / Research Triangle Park, NC

Genetic Susceptibility of Humans - Xenobiotic Metabolism

Frank J. Gonzalez / Bethesda, MD
Fred F. Kadlubar / Jefferson, AR
Peter G. Shields / Bethesda, MD
C. Roland Wolf / Dundee, Scotland

Genetic Susceptibility of Humans - DNA Repair

Isabel Mellon / Lexington, KY

Genetic Susceptibility of Humans - Tumor Suppressor Genes

Louise C. Strong / Houston, TX
Curtis C. Harris / Bethesda, MD

Senescence and Terminal Differentiation

J. Carl Barrett / Research Triangle Park, NC
Carol W. Greider / Cold Springs Harbor, NY
Jennifer A. Pietenpol / Nashville, TN
Harold L. Moses / Nashville, TN

Apoptosis

Tona M. Gilmer / Research Triangle Park, NC
Judith Campisi / Berkeley, CA
Michael B. Kastan / Baltimore, MD
Eileen White / Piscataway, NJ
Scott W. Lowe / Cambridge, MA

Molecular Carcinogenesis in Animal Models and Humans - Skin

Allan Balmain / Glasgow, Scotland
Douglas E. Brash / New Haven, CT

Molecular Carcinogenesis in Animal Models and Humans - Liver and Breast

Henry C. Pitot / Madison, WI
Xin W. Wang / Bethesda, MD
Roger W. Wiseman / Research Triangle Park, NC

Molecular Carcinogenesis in Animal Models and Humans - Brain

Terry A. Van Dyke / Chapel Hill, NC
Paul Kleihues / Lyon, France

Additional Speakers to be Announced

*Applicants are encouraged to submit abstracts
for poster presentation.*

Application deadline: November 3, 1995

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for **associate** membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives

applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office

January 1
May 1
September 1

Notification of Candidate

March
July
November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. -OR- The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). -OR- The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215-440-9313

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1995 annual dues for active members are \$160, \$95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$80 in 1995) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

PRESENT POSITION/TITLE: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

E-MAIL NUMBER (CARRIER): _____

PRIMARY FIELD OF RESEARCH (Please check only one):

<input type="checkbox"/> Biochemistry and Biophysics	<input type="checkbox"/> Biostatistics	<input type="checkbox"/> Carcinogenesis
<input type="checkbox"/> Cellular Biology and Genetics	<input type="checkbox"/> Clinical Investigations	<input type="checkbox"/> Endocrinology
<input type="checkbox"/> Epidemiology	<input type="checkbox"/> Immunology	<input type="checkbox"/> Molecular Biology and Genetics
<input type="checkbox"/> Preclinical Pharmacology and Experimental Therapeutics	<input type="checkbox"/> Virology	<input type="checkbox"/> Other: _____ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

CANDIDATE
NOMINATED BY*: _____
(Please print)

CANDIDATE
SECONDED BY*: _____
(Please print)

CANDIDATE IS APPLYING FOR (Check one): ☐ ACTIVE ☐ CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT (in place of letters of recommendation)

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

How long has the candidate worked in the field of cancer research? ____ years

Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No

Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* Date

Signature of seconder* Date

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.

(This form may be reproduced.)



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the *Proceedings of the American Association for Cancer Research* which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association's high-quality journals *Cancer Research*, *Cell Growth & Differentiation*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at reduced member rates;
6. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original

signatures of both the candidate and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues for 1994 are \$30 for associate members residing in the Americas and \$40 for residents of other countries. For 1995 these rates are \$35 and \$45, respectively. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1994 have been set at \$30 per year for residents of the Americas and \$40 for residents of other countries. For 1995 these rates are \$35 and \$45, respectively. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1994 for the forthcoming annual meeting must have paid dues for 1994. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Cell Growth & Differentiation*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1994 may retain associate membership until December 31, 1998. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building · Suite 816 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER: _____ FAX NUMBER: _____

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER): _____
☐ Graduate Student ☐ Medical Student
☐ Physician in Training ☐ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):
☐ Biochemistry and Biophysics ☐ Biostatistics ☐ Carcinogenesis
☐ Cellular Biology and Genetics ☐ Clinical Investigations ☐ Endocrinology
☐ Epidemiology ☐ Immunology ☐ Molecular Biology and Genetics
☐ Preclinical Pharmacology and ☐ Virology ☐ Other: _____
Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY: _____
(Please type or print name of AACR member* in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: _____ Date: _____

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: _____ Date: _____

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. For 1994 dues are \$30 for associate members residing in the Americas and \$40 for residents of other countries. For 1995, these rates will be \$35 and \$45, respectively.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:
The enclosed dues payment should be applied to the ☐ current ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March or April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)

**Guidelines for Submitting Disks
to
American Association for Cancer Research Publications**

The word processing packages that we prefer are as follows:

XyWrite III Plus (for the IBM)	Microsoft Word (for the IBM)
WordPerfect 4.2, 5.0, 5.1 (for the IBM)	Microsoft Word Macintosh
WordPerfect (for the Mac)	(Versions 1-4) 400/800K
Wordstar (for the IBM)	Wang OIS (WPS)

Also acceptable:

Apple II DOS 3.3	Display Write 4
Apple with Appleworks Software	IBM Displaywriter Word Processor 6580
Apple III Plus DOS 3.3	Lanier Business One Step
Apple Macintosh 400K Disc/ MacWrite 2.2 (text)	Lanier No Problem
Apple Macintosh Plus 800K Disc/ MacWrite 4.5 (text)	Lanier Super No Problem
CPT 8000	MASS-11 PC
DEC WPS-8	Multimate
DEC Decmate II	PC Write
DEC Decmate III	PFS Professional Write
Display Write 3	Volkswriter 4.0

New releases of word processing software are not always immediately available for conversion. In addition, because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.



DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk: _____

Name of computer used (e.g., IBM/PS2): _____

Operating system and version (e.g., DOS 3.3): _____

Word processing program and version (e.g., WordPerfect 5.0): _____

[See reverse for acceptable programs.]

Manuscript number: _____

First author: _____

Corresponding author (if different from first author): _____

Telephone/FAX numbers: _____

This form (both sides) may be reproduced.

**86th Annual Meeting • American Association for Cancer Research**

Programs consist of either 1 tape/\$11.50, 2 tapes/\$23.00, or 3 tapes/\$34.50 (PRICES INDICATED BEFORE EACH TITLE)

AUDIO CASSETTE DISCOUNTS

1-5 cassettes	\$11.50
6-11 cassettes	5% DISCOUNT
12-24 cassettes	10% DISCOUNT
25-48 cassettes	15% DISCOUNT
49 +	20% DISCOUNT

Programs consist of 1, 2, or 3 cassettes. Prices are listed after each program title.

- ☐ CAN 501 (3 cass, \$34.50) Methods Workshop 1: General, *in Situ*, and Quantitative PCR
- ☐ CAN 502 (3 cass, \$34.50) Methods Workshop 2: Gene Targeting and Gene Trapping in Mice
- ☐ CAN 503 (2 cass, \$23.00) Educational Session 1: Molecular Modeling to Medical Monitoring: The Development of New Anticancer Agents
- ☐ CAN 504 (2 cass, \$23.00) Educational Session 2: Gene Therapy
- ☐ CAN 505 (2 cass, \$23.00) Educational Session 3: Genetic Instability in Cancer
- ☐ CAN 506 (2 cass, \$23.00) Educational Session 4: Cytochrome P450
- ☐ CAN 507 (1 cass, \$11.50) Meet the Expert Sunrise Session: Pediatric Oncology, Joseph V. Simone
- ☐ CAN 508 (1 cass, \$11.50) Meet the Expert Sunrise Session: A Primer on Analyzing Clinical Trials, Steven Piantadosi
- ☐ CAN 509 (1 cass, \$11.50) Meet the Expert Sunrise Session: Farnesyltransferase as a Target for Therapy, Alexander W. Wood
- ☐ CAN 510 (1 cass, \$11.50) Meet the Expert Sunrise Session: P-Glycoprotein Biology and Multidrug Resistance, Victor Ling
- ☐ CAN 511 (1 cass, \$11.50) Meet the Expert Sunrise Session: Is a Mutagenic Event Involved in Initiation? Ann R. Kennedy
- ☐ CAN 512 (3 cass, \$34.50) Minisymposium Immunology/Biological Therapy 1: Tumor Immunogenicity and Effector Cells
- ☐ CAN 513 (3 cass, \$34.50) Minisymposium Carcinogenesis 1: Detection of Carcinogen-DNA Adducts in Humans
- ☐ CAN 514 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 1: Molecular Studies of Selected Agents
- ☐ CAN 515 (3 cass, \$34.50) Minisymposium Organ Site/Translational Session 1: Molecular and Cellular Aspects of Gynecological Malignancies
- ☐ CAN 516 (3 cass, \$34.50) Minisymposium Molecular Biology/Biochemistry 1: New Tumor Suppressor Genes
- ☐ CAN 517 (2 cass, \$23.00) Plenary Session: Integrated View of the Cancer Cell
- ☐ CAN 519 (1 cass, \$11.50) Controversy Session 1: Breast Cancer Prevention: What Will We Advise Women With BRCA1?
- ☐ CAN 520 (3 cass, \$34.50) Minisymposium Clinical Investigations 2: Tumor Vaccine and Cytolytic T-Cell Generation
- ☐ CAN 521 (3 cass, \$34.50) Minisymposium Molecular Biology/Biochemistry 4: Retinoids and Their Receptors
- ☐ CAN 522 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 6: Molecular Studies of Folate
- ☐ CAN 523 (3 cass, \$34.50) Minisymposium Biology 4: Advances in Invasion, Metastasis, and Angiogenesis Research
- ☐ CAN 524 (2 cass, \$23.00) Symposium 1: Growth Factors, Their Receptors, and Differentiation
- ☐ CAN 525 (2 cass, \$23.00) Symposium 2: Oligonucleotide-mediated Modulation of Mammalian Gene Expression
- ☐ CAN 526 (2 cass, \$23.00) Symposium 3: Biomarkers of Carcinogenesis
- ☐ CAN 527 (2 cass, \$23.00) Symposium 4: DNA Repair Pathways: Recent Surprises
- ☐ CAN 528 (2 cass, \$23.00) Symposium 5: Mechanistic Basis of Ethnic Differences in Cancer Risk
- ☐ CAN 529 (1 cass, \$11.50) Presidential Address: There's More Than One Way to Skin a Cat or Regulation of the Polycyclic Hydrocarbon-inducible Cytochrome P4501A1 Gene, Edward Bresnick; Presentation of the Third Gertrude Elion Cancer Research Award
- ☐ CAN 530 (2 cass, \$23.00) Careers and Opportunities in Cancer Research: Models for Success: A Symposium Organized by the Committee on Minority Issues
- ☐ CAN 531 (1 cass, \$11.50) Meet the Expert Sunrise Session: Everything You Always Wanted to Know About Prostatic Cancer But Were Afraid to Ask, John T. Isaacs
- ☐ CAN 532 (1 cass, \$11.50) Meet the Expert Sunrise Session: Colon Cancer, Ronald N. Buick
- ☐ CAN 533 (1 cass, \$11.50) Meet the Expert Sunrise Session: Peripheral Blood Progenitor Cell Transplantation, Elizabeth J. Shpall
- ☐ CAN 534 (1 cass, \$11.50) Meet the Expert Sunrise Session: Multivariate Determinants of Radiocurability: Predictive Assays in Radiation Oncology, Richard P. Hill
- ☐ CAN 535 (1 cass, \$11.50) Meet the Expert Sunrise Session: Glutathione and Associated Enzymes in Anticancer Drug Response, Kenneth D. Tew
- ☐ CAN 536 (3 cass, \$34.50) Symposium 6: Genetic Susceptibility to Cancer
- ☐ CAN 537 (2 cass, \$23.00) Symposium 7: Combinatorial Libraries for Cancer Research and Drug Discovery
- ☐ CAN 538 (2 cass, \$23.00) Symposium 8: Telomeres and Telomerases
- ☐ CAN 539 (2 cass, \$23.00) Symposium 9: Immunotherapy: Tumor Vaccines
- ☐ CAN 540 (2 cass, \$23.00) Symposium 10: Glycosylation Defining Malignancy
- ☐ CAN 541 (3 cass, \$34.50) Minisymposium Radiobiology/Radiation Oncology 2: Radiation-induced Gene Expression
- ☐ CAN 542 (3 cass, \$34.50) Minisymposium Clinical Investigations 4: New Drugs: Phase I Studies
- ☐ CAN 543 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 12: Transcriptional/Translational Control of Drug Resistance Genes
- ☐ CAN 544 (3 cass, \$34.50) Minisymposium Biology 8: Signal Transduction II
- ☐ CAN 545 (1 cass, \$11.50) Controversy Session 2: Does the Current Body Burden of Dioxin Pose a Risk to the Health of the North American Population?
- ☐ CAN 546 (1 cass, \$11.50) Fourth American Cancer Society Award Lecture: Inherited Susceptibility to Cancer: From Epidemiology to Interventional Research, Frederick P. Li
- ☐ CAN 547 (1 cass, \$11.50) Public Education Session: Consumer Involvement in the Breast Cancer Research Process: *Frances M. Visco*
- ☐ CAN 548 (1 cass, \$11.50) Controversy Session 3: What Are the Benefits and Limits of Prostate-specific Antigen as a Screening Tool?
- ☐ CAN 549 (3 cass, \$34.50) Minisymposium Carcinogenesis 11: Carcinogen Activation in Humans
- ☐ CAN 550 (3 cass, \$34.50) Minisymposium Molecular Biology/Biochemistry 10: Signal Transduction and Tumorigenesis
- ☐ CAN 551 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 18: Targeting Topoisomerases I
- ☐ CAN 552 (3 cass, \$34.50) Minisymposium Organ Site/Translational Session 4: Oncogenes, Tumor Suppressor Genes, and Growth Factors in Breast Cancer
- ☐ CAN 553 (3 cass, \$34.50) Minisymposium Biology 11: Apoptosis III
- ☐ CAN 554 (2 cass, \$23.00) Symposium 11: New Strategies and Targets for Therapy of Cancer
- ☐ CAN 556 (2 cass, \$23.00) Symposium 12: The Biology of Radiation Oncology
- ☐ CAN 557 (2 cass, \$23.00) Symposium 13: Genes, Development, and Cancer
- ☐ CAN 558 (2 cass, \$23.00) Symposium 14: Dietary Intervention in Hormonal Carcinogenesis
- ☐ CAN 560 (2 cass, \$23.00) AACR Annual Business Meeting
- ☐ CAN 561 (1 cass, \$11.50) Meet the Expert Sunrise Session: Human Gene Therapy in Urological Oncology, Jonathan W. Simons
- ☐ CAN 562 (1 cass, \$11.50) Meet the Expert Sunrise Session: Chemical and Viral Etiologies of Liver Cancer: Application of Mechanistic Knowledge to Preventive Interventions, John D. Groopman
- ☐ CAN 563 (1 cass, \$11.50) Meet the Expert Sunrise Session: Biochemical Determinants of Carcinogenesis: The AH Receptor and Human Responses to Dioxins, Allan B. Okey
- ☐ CAN 564 (1 cass, \$11.50) Meet the Expert Sunrise Session: Organ-specific Carcinogenesis (Location, Location, Location) Cheryl Lyn Walker
- ☐ CAN 565 (1 cass, \$11.50) NIH Grants Session: Succeeding in a Changing Environment
- ☐ CAN 566 (2 cass, \$23.00) Symposium 15: Translational Research in Breast Cancer
- ☐ CAN 567 (2 cass, \$23.00) Symposium 16: DNA Methylation
- ☐ CAN 568 (2 cass, \$23.00) Symposium 17: Genetic Approaches to Invasion and Metastasis
- ☐ CAN 569 (2 cass, \$23.00) Symposium 18: The Role of Stromal-Epithelial Interactions in Growth and Neoplasia
- ☐ CAN 570 (3 cass, \$34.50) Minisymposium Immunology/Biological Therapy 7: New Developments in Tumor Immunobiology
- ☐ CAN 571 (3 cass, \$34.50) Minisymposium Epidemiology 3: Carcinogen Metabolism and Biomarkers
- ☐ CAN 572 (3 cass, \$34.50) Minisymposium Clinical Investigations 7: Experimental and Clinical Gene Therapy
- ☐ CAN 573 (3 cass, \$34.50) Minisymposium Biology 15: Cell Cycle II
- ☐ CAN 574 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 24: Targeting *ras*
- ☐ CAN 575 (1 cass, \$11.50) Controversy Session 4: Is Mammography Before Age 50 Beneficial?
- ☐ CAN 577 (1 cass, \$11.50) Late-Breaking Research Session
- ☐ CAN 578 (3 cass, \$34.50) Minisymposium Organ Site/Translational Session 6: Gastrointestinal Cancer: Susceptibility, Diagnosis, and Prognosis

- ☐ CAN 579 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 30: *MRP* and Other Novel Drug Resistance Genes and Mechanisms
- ☐ CAN 580 (3 cass, \$34.50) Minisymposium Carcinogenesis 19: Cell Cycle Genes in Carcinogenesis
- ☐ CAN 581 (3 cass, \$34.50) Minisymposium Biology 19: Moving Invasion, Metastasis, and Angiogenesis Research toward Clinical Applications
- ☐ CAN 582 (3 cass, \$34.50) Minisymposium Molecular Biology/Biochemistry 16: Alterations of the Cancer Genome
- ☐ CAN 583 (2 cass, \$23.00) Symposium 19: Contribution of Environmental Factors to Cancer
- ☐ CAN 584 (2 cass, \$23.00) Symposium 20: Stem Cell Transplantation and High-Dose Chemotherapy
- ☐ CAN 585 (2 cass, \$23.00) Symposium 21: Signal Transduction and Gene Control and Development
- ☐ CAN 586 (2 cass, \$23.00) Symposium 22: Natural Products in Chemoprevention of Cancer
- ☐ CAN 587 (1 cass, \$11.50) Fourteenth Cornelius P. Rhoads Memorial Award Lecture: Mapping Genes and Genomes: Genetic Dissection of Complex Traits, Eric S. Lander
- ☐ CAN 588 (1 cass, \$11.50) Meet the Expert Sunrise Session: Pharmacokinetic/ Pharmacodynamic Relationships in Cancer Chemotherapy, Merrill J. Egorin
- ☐ CAN 589 (1 cass, \$11.50) Meet the Expert Sunrise Session: Cellular and Molecular Biology Underlying Relationships between the Major Forms of Human Lung Cancer, Stephen B. Baylin
- ☐ CAN 590 (1 cass, \$11.50) Meet the Expert Sunrise Session: Prostate-specific Gene Expression in Transgenic Mice, Norman M. Greenberg
- ☐ CAN 591 (1 cass, \$11.50) Meet the Expert Sunrise Session: Tyrosine Phosphorylation in Transcytoplasmic Signaling, Tony Hunter
- ☐ CAN 592 (1 cass, \$11.50) Meet the Expert Sunrise Session: Molecular Determinants of Multidrug Resistance: p53 Mutations Are Associated with Resistance of Hematopoietic Malignancies to Chemotherapy, Elizabeth W. Newcomb
- ☐ CAN 593 (2 cass, \$23.00) Symposium 23: The Cell Cycle and Tumor Suppressor Genes
- ☐ CAN 594 (2 cass, \$23.00) Symposium 24: Transcription Factors in Development and

- Neoplasia
- ☐ CAN 595 (2 cass, \$23.00) Symposium 25: Human Gene Therapy in Clinical Cancer
 - ☐ CAN 596 (2 cass, \$23.00) Symposium 26: *Graft versus* Tumor Effects
 - ☐ CAN 597 (3 cass, \$34.50) Minisymposium Prevention 5: Chemoprevention: Inhibitors of the Arachidonic Acid Cascade
 - ☐ CAN 598 (3 cass, \$34.50) Minisymposium Endocrinology 5: Prostate Cancer II
 - ☐ CAN 599 (3 cass, \$34.50) Minisymposium Organ Site/Translational Session 7: Lung and Head and Neck Translational Research
 - ☐ CAN 5100 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 36: Novel Agents
 - ☐ CAN 5101 (3 cass, \$34.50) Minisymposium Carcinogenesis 22: Human Genetics and Cancer Susceptibility
 - ☐ CAN 5102 (1 cass, \$11.50) Controversy Session 5: Is Bone Marrow Transplantation Indicated for Breast Cancer?
 - ☐ CAN 5103 (1 cass, \$11.50) Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap
 - ☐ CAN 5104 (1 cass, \$11.50) Controversy Session 6: Are Estrogens Implicated in Breast Cancer?
 - ☐ CAN 5105 (3 cass, \$34.50) Minisymposium Molecular Biology/Biochemistry 22: Regulation of Enzymes that Metabolize Drugs and Carcinogens
 - ☐ CAN 5106 (3 cass, \$34.50) Minisymposium Immunology/Biological Therapy 12: Immunobiological and Therapeutic Aspects of Central Nervous System Tumors
 - ☐ CAN 5107 (3 cass, \$34.50) Minisymposium Clinical Investigations 13: Hematopoietic Stem Cell Transplantation/High-Dose Chemotherapy
 - ☐ CAN 5108 (3 cass, \$34.50) Minisymposium Carcinogenesis 26: Signal Transduction, Growth Factors, and Cellular Communication
 - ☐ CAN 5109 (3 cass, \$34.50) Minisymposium Experimental Therapeutics 42: Drug Resistance: New Strategies and Targets
 - ☐ CAN 5110 (2 cass, \$23.00) Symposium 27: Angiogenic Control of Tumor Growth
 - ☐ CAN 5111 (2 cass, \$23.00) Symposium 28: Extracellular Matrix, Gene Expression and Cell Signalling
 - ☐ CAN 5112 (2 cass, \$23.00) Symposium 29: Apoptosis
 - ☐ CAN 5113 (2 cass, \$23.00) Symposium 30: Cancer Prevention and Intermediate Biomarkers

THE FOLLOWING PROGRAMS ARE AVAILABLE ON

VIDEO CASSETTE

EACH VIDEO PROGRAM CONSISTS OF
ONE VIDEO, \$39.00 UNLESS OTHERWISE NOTED

- ☐ CAN 517V (2 cass, \$58.00) Plenary Session: Integrated View of the Cancer Cell
- ☐ CAN 529V Presidential Address: There's More Than One Way to Skin a Cat or Regulation of the Polycyclic Hydrocarbon-inducible Cytochrome P4501A1 Gene, Edward Bresnick; Presentation of the Third Gertrude Elion Cancer Research Award
- ☐ CAN 546V Fourth American Cancer Society Award Lecture: Inherited Susceptibility to Cancer: From Epidemiology to Interventional Research, Frederick P. Li
- ☐ CAN 587V Fourteenth Cornelius P. Rhoads Memorial Award Lecture: Mapping Genes and Genomes: Genetic Dissection of Complex Traits, Eric S. Lander
- ☐ CAN 5103V Fourteenth Bruce F. Cain Memorial Award Lecture: Initiatives with Platinum- and Quinazoline-based Antitumor Molecules, Kenneth R. Harrap

VIDEO CASSETTE DISCOUNT

Save 10% on entire set of videotapes

PLEASE COMPLETE AND RETURN ENTIRE FORM

PLEASE PRINT

CAN

SUB-TOTAL AUDIOTAPE ORDER \$ _____

SUB-TOTAL VIDEO TAPE ORDER \$ _____

(IL RESIDENTS ADD 8.75% SALES TAX) \$ _____

AUDIO \$4.00 SHIPPING & HANDLING \$ \$4.00

VIDEO \$4.00 S & H (\$24 MAX) \$ _____

TOTAL (IN U.S. FUNDS) \$ _____

VIDEO ORDERS

(Please check one)

- ☐ VHS
- ☐ PAL (\$15 conversion surcharge)

☐ CHECK ENCLOSED PAYABLE TO TEACH 'EM

☐ VISA \$25 MINIMUM ON CREDIT CARD ORDERS

☐ MC CARD # _____

☐ AMEX EXPIRATION DATE _____

NAME _____ TITLE _____

ORGANIZATION _____

ADDRESS (NO PO BOXES) _____ CITY _____ STATE _____ ZIP _____

SIGNATURE _____ TELEPHONE () _____

PLEASE NOTE: Any defective tapes will be replaced, but tapes are nonrefundable.

Cancer Epidemiology Biomarkers & Prevention

Continued

Relationships of Age and Reproductive Characteristics with Plasma Estrogens and Androgens in Premenopausal Women	381
Joanne F. Dorgan, Marsha E. Reichman, Joseph T. Judd, Charles Brown, Christopher Longcope, Arthur Schatzkin, William S. Campbell, Charlene Franz, Lisa Kahle, and Philip R. Taylor	
Chemopreventive Effect of Green Tea (<i>Camellia sinensis</i>) among Cigarette Smokers	387
J. S. Shim, M. H. Kang, Y. H. Kim, J. K. Roh, C. Roberts, and I. P. Lee	
Analysis of Plasma and Urinary Tea Polyphenols in Human Subjects	393
Mao-Jung Lee, Zhi-Yuan Wang, He Li, Laishun Chen, Yang Sun, Steve Gobbo, Douglas A. Balentine, and Chung S. Yang	
Preventive Effect of Ginseng Intake against Various Human Cancers: A Case-Control Study on 1987 Pairs	401
Taik-Koo Yun and Soo-Yong Choi	
Repeat Mammography Use among Women Ages 50–75	409
Victoria M. Taylor, Stephen H. Taplin, Nicole Urban, Emily White, and Susan Peacock	

Review

Molecular Virology and Epidemiology of Human Papillomavirus and Cervical Cancer	415
Joel M. Palefsky and Elizabeth A. Holly	

Meeting Report

Nineteenth Annual Meeting of the American Society of Preventive Oncology	429
Elizabeth T. H. Fontham	

AACR Bulletin Board	435
---------------------	------------

ASPO Bulletin Board	436
---------------------	------------

Instructions for Authors	<i>i</i>
--------------------------	----------

June 1995
Volume 4
Number Four
Pages 301-436
ISSN 1055-9965

Cancer Epidemiology & Prevention Biomarkers



An Official Journal of the
American Association for Cancer Research
Cospponsored by the
American Society of Preventive Oncology

- Incorporating Biomarkers into Cancer Epidemiology: A Matrix of Biomarker and Study Design Categories** 301
Nathaniel Rothman, Walter F. Stewart, and Paul A. Schulte

Research Articles

- Synergistic Effect between Alcohol and Estrogen Replacement Therapy on Risk of Breast Cancer Differs by Estrogen/Progesterone Receptor Status in the Iowa Women's Health Study** 313
Susan M. Gapstur, John D. Potter, Carol Drinkard, and Aaron R. Folsom
- Progesterone and Estrogen Receptors and Mammary Neoplasia in the Iowa Women's Health Study: How Many Kinds of Breast Cancer Are There?** 319
John D. Potter, James R. Cerhan, Thomas A. Sellers, Paul G. McGovern, Carol Drinkard, Lawrence R. Kushi, and Aaron R. Folsom
- Risk of Renal Cell Cancer in Relation to Diuretics, Antihypertensive Drugs, and Hypertension** 327
Wong-Ho Chow, Joseph K. McLaughlin, Jack S. Mandel, Sholom Wacholder, Shelley Niwa, and Joseph F. Fraumeni, Jr.
- Spinal Meningiomas in Women in Los Angeles County: Investigation of an Etiological Hypothesis** 333
Susan Preston-Martin, Kristine Monroe, Pey-jiuan Lee, Leslie Bernstein, Jennifer Kelsey, Sean Henderson, Deborah Forrester, and Brian Henderson
- A Molecular Epidemiological Case-Control Study of Lung Cancer** 341
Deliang Tang, Regina M. Santella, Anne M. Blackwood, Tie-Lan Young, Jack Mayer, Alfred Jaretzki, Samuel Grantham, Wei-Yan Tsai, and Frederica P. Perera
- A Pilot Study of DNA Aneuploidy in Colorectal Adenomas and Risk of Adenoma Recurrence** 347
Alan R. Kristal, Mary S. Baker, Michael J. Flaherty, Ziding Feng, Thomas J. Ylvisaker, Andrew D. Feld, and Douglas S. Levine
- Fecal Lignan and Isoflavonoid Excretion in Premenopausal Women Consuming Flaxseed Powder** 353
Mindy S. Kurzer, Johanna W. Lampe, Margaret C. Martini, and Herman Adlercreutz
- Comparison of Proliferating Cell Nuclear Antigen *versus* the More Standard Measures of Rectal Mucosal Proliferation Rates in Subjects with a History of Colorectal Cancer and Normal Age-matched Controls** 359
Janine Einspahr, David Alberts, Tailiang Xie, Justine Ritchie, David Earnest, Lee Hixson, Marianne Powell, Denise Roe, and Thomas Grogan
- Altered Expression of Class I HLA Antigen on Peripheral Mononuclear Cells in Patients with Adult T-Cell Leukemia: Inverse Relationship with Natural Killer Susceptibility** 367
Hisamitsu Uno, Hitoshi Matsuoka, Muneou Suzuki, Kazunori Tsuda, and Hirohito Tsubouchi
- A Longitudinal Analysis of Human Papillomavirus 16 Infection, Nutritional Status, and Cervical Dysplasia Progression** 373
Tiepu Liu, Seng-jaw Soong, Ronald D. Alvarez, and Charles E. Butterworth, Jr.

Continued on Inside Back Cover